The risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone. Pegvisomant may increase the hypoglycemic activities of Metformin. Moclobemide may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Glycopyrronium. Mebanazine may increase the hypoglycemic activities of Metformin. Rosoxacin may increase the hypoglycemic activities of Metformin. Sertraline may increase the hypoglycemic activities of Metformin. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone. Metformin may increase the hypoglycemic activities of Disopyramide. The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid. Fleroxacin may increase the hypoglycemic activities of Metformin. Nandrolone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol. The therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide. Rasagiline may increase the hypoglycemic activities of Metformin. Testosterone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide. Metformin may increase the hypoglycemic activities of Insulin Glargine. The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone. Metformin may increase the hypoglycemic activities of Glipizide. Iproniazid may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib. The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin. The therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide. The risk or severity of heart failure can be increased when Pregabalin is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide. GLPG-0492 may increase the hypoglycemic activities of Metformin. Gemifloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone. Metformin may increase the hypoglycemic activities of Mecasermin. The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine. The risk or severity of adverse effects can be increased when Diatrizoate is combined with Metformin. Duloxetine may increase the hypoglycemic activities of Metformin. Pazufloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone. The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol. The therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine. Dihydrotestosterone may increase the hypoglycemic activities of Metformin. Tranylcypromine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Brinzolamide is combined with Metformin. Citalopram may increase the hypoglycemic activities of Metformin. Prulifloxacin may increase the hypoglycemic activities of Metformin. Procarbazine may increase the hypoglycemic activities of Metformin. Trovafloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin. The therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel. The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine. Trolamine salicylate may increase the hypoglycemic activities of Metformin. Fluoxymesterone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Detemir. The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol. The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir. Metformin may increase the hypoglycemic activities of Insulin Glulisine. The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir. Venlafaxine may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Cimetidine. Milnacipran may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine. Mesalazine may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Mifepristone. The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide. The therapeutic efficacy of Metformin can be decreased when used in combination with Articaine. The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel. Olsalazine may increase the hypoglycemic activities of Metformin. Fluoxetine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate. Oxymetholone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Sunitinib. The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone. The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat. The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin. The risk or severity of adverse effects can be increased when Ioxilan is combined with Metformin. The serum concentration of Dalfampridine can be increased when it is combined with Metformin. Methyl salicylate may increase the hypoglycemic activities of Metformin. Furazolidone may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Bupropion. The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus. The risk or severity of adverse effects can be increased when Dorzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel. The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide. The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone. Octamoxin may increase the hypoglycemic activities of Metformin. Nalidixic Acid may increase the hypoglycemic activities of Metformin. Testosterone Propionate may increase the hypoglycemic activities of Metformin. Sparfloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide. The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide. The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole. The therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate. The serum concentration of Trospium can be decreased when it is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin. Balsalazide may increase the hypoglycemic activities of Metformin. Nandrolone decanoate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir. Dapoxetine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole. Salicylic acid may increase the hypoglycemic activities of Metformin. Grepafloxacin may increase the hypoglycemic activities of Metformin. Toloxatone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Sulfadiazine. Harmaline may increase the hypoglycemic activities of Metformin. Levofloxacin may increase the hypoglycemic activities of Metformin. Diflunisal may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir. Carbaspirin calcium may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib. The risk or severity of adverse effects can be increased when Methazolamide is combined with Metformin. Methyltestosterone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate. Metformin may increase the hypoglycemic activities of Sulfisoxazole. Desvenlafaxine may increase the hypoglycemic activities of Metformin.